{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["PD-L1 t-haNK","NAI","cetuximab"]],"indication":"immunotherapy-treated recurrent metastatic HNSCC","name":"QUILT-505","nct_id":"NCT06239220","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=quilt-505-nct06239220. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Dose level modifications of PD-L1 t-haNK and NAI due to toxicities will follow protocol specifications, starting at Dose Level 0 and de-escalating to Dose Level -1. Participants will complete:\n\n* Baseline visit.\n* Imaging scans every 8 weeks while on study.\n* Cycle 1 through End of Treatment:\n\n  --Days 1 and 15 of 28 day cycle in the following order: Predetermined dose of PD-L1 t-haNK 1x daily, predetermined dose of NAI 1x daily, and predetermined dose of Cetuximab 1x daily.\n* End of Treatment visit with assessments.\n* Follow up: follow up every 3-4 months for up to 3 years after end of treatment. Longer-term follow-up every 6-12 months for up to 15 years.","label":"Dose Level 0: PD-L1 t-haNK + NAI + Cetuximab","type":"EXPERIMENTAL"},{"description":"Dose level modifications of PD-L1 t-haNK and NAI due to toxicities will follow protocol specifications. Participants will complete:\n\n* Baseline visit.\n* Imaging scans every 8 weeks while on study.\n* Cycle 1 through End of Treatment:\n\n  --Days 1 and 15 of 28 day cycle in the following order: Predetermined dose of PD-L1 t-haNK 1x daily, predetermined dose of NAI 1x daily, and predetermined dose of Cetuximab 1x daily.\n* End of Treatment visit with assessments.\n* Follow up: follow up every 3-4 months for up to 3 years after end of treatment. Longer-term follow-up every 6-12 months for up to 15 years.","label":"Dose Level -1: PD-L1 t-haNK + NAI + Cetuximab","type":"EXPERIMENTAL"}],"collaborators":["ImmunityBio, Inc."],"completion_date":{"date":"2027-03-31","type":"ESTIMATED"},"conditions":["Head and Neck Cancer","Head and Neck Squamous Cell Carcinoma","Metastatic Head and Neck Cancer","Recurrent Head and Neck Cancer","Metastatic Head-and-neck Squamous-cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma"],"enrollment":{"count":25,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"PD-L1 t-haNK","otherNames":["NK-92"],"type":"BIOLOGICAL"},{"name":"Cetuximab","otherNames":["Erbitux"],"type":"DRUG"},{"name":"NAI","otherNames":["Interleukin-15","IL-15","Anktiva","N-803"],"type":"BIOLOGICAL"}],"last_update":"2026-10-19","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"A Phase 2 Trial of PD-L1 t-haNK, NAI IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"Disease will be evaluated through imaging every 2 cycles on day 1 and 15 (each cycle is 28 days) and through study completion (an average of 1 year). ORR expected to be observed up to 1 year."}],"references":[],"start_date":{"date":"2024-02-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC","url":"https://clinicaltrials.gov/study/NCT06239220"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/quilt-505-nct06239220"}